The apatient cost of the Sovaldi hepatitis C treatment has intensified a national debate among lawmakers insurers and economists about the value of expensive medicines to society at large The dilemma sparked by Sovaldi which is made by Gilead Sciences is also presenting hard choices to state Medicaid programs In Illinois for instance officials recently instituted a new set of  stringent criteria for using Sovaldi that includes treating only those patients with the most advanced stage of liver disease and limiting treatment for those with a history of drug use and alcohol abuse  The
  